15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 18 firms covering Zimmer Biomet Holdings Inc, 6 rate it Buy or better, 11 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $90.00 to $115.00, so the covering firms are broadly aligned. The average target of $101.81 sits 8% above the current $94.21. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.49 next quarter toward $9.07 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 ratings
Moderate Buy
Strong Buy00%
Buy633%
Hold1161%
Sell16%
Strong Sell00%
Based on 18 analysts giving stock ratings to Zimmer Biomet Holdings Inc.
As of Sep, 5 of 17 firms rate ZBH a Buy (11 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
ZBH EPS & revenue forecast
EPS · NEXT QUARTER
$2.49
Range $2.43 – $2.54 · 24 analysts · +3% YoY
Next period, 24 analysts expect Zimmer Biomet Holdings Inc to earn $2.49 a share (range $2.43 – $2.54), versus $2.42 a year earlier. Full-year consensus is $8.53, growing to $9.07 the year after.
REVENUE · NEXT QUARTER
$2.3B
Range $2.0B – $2.3B · 24 analysts · +2% YoY
Revenue is expected to reach $2.3B (range $2.0B – $2.3B), +1.8% year-over-year. Full-year consensus is $8.6B, rising to $8.9B next year.
Top analysts covering Zimmer Biomet Holdings Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZBH.
#1
JB
Jayson Bedford
Raymond James · Rank #196
Hold
No targeton ZBH
Overall win rate
42%
+ Follow
#2
Mike Matson
Needham · Rank #210
Hold
No targeton ZBH
Overall win rate
34%
+ Follow
#3
JW
Jason Wittes
Roth MKM · Rank #311
Buy
$138.00+46.5% to target
Overall win rate
39%
+ Follow
#4
David Turkaly
JMP Securities · Rank #346
Buy
$105.00+11.5% to target
Overall win rate
33%
+ Follow
#5
Joanne Wuensch
Citigroup
Hold
$99.00+5.1% to target
Coverage
—
+ Follow
ZBH stock forecast FAQ
What is ZBH's average 12-month price target?+
The 15 analysts with a live target average $101.81 for Zimmer Biomet Holdings Inc over the next 12 months, ranging from a $115.00 high to a $90.00 low.
Is ZBH stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 18 analyst ratings, 6 are Buy or Strong Buy, 11 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for ZBH?+
The Street-high target is $115.00 (UBS), and the Street-low is $90.00 (Wells Fargo). The average of all 15 active targets is $101.81.
How many Wall Street analysts cover ZBH?+
18 analysts have an active rating on Zimmer Biomet Holdings Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZBH?+
Among analysts who currently cover ZBH, Jayson Bedford of Raymond James has the strongest overall Quantellect track record (Rank #196). Their current call is Hold.
What is Zimmer Biomet Holdings Inc's projected EPS for next quarter?+
The consensus estimate is $2.49 per share (range $2.43 – $2.54) across 24 analysts. Full-year EPS is projected at $8.53, rising to $9.07 the following year.
How much revenue is Zimmer Biomet Holdings Inc expected to report next quarter?+
Consensus revenue is $2.3B (range $2.0B – $2.3B). Full-year revenue is projected at $8.6B, growing to $8.9B next year.
Have analysts been upgrading or downgrading ZBH lately?+
As of Sep, 5 of 17 firms rate ZBH a Buy (11 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZBH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
UBS
BMO Capital
